Claybrook Capital’s Quest Diagnostics DGX Stock Holding History

Claybrook Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-150	Closed	-$12K	–	226
2018 Q4	$12K	Buy	+150	New	+$14.1K	﹤0.01%	438

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Claybrook Capital's DGX Position: Q1 2019 in Review

Claybrook Capital sold out of Quest Diagnostics (DGX) in Q1 2019, closing a stake of 150 shares — an estimated $12K sold.

Claybrook Capital first reported a position in DGX in Q4 2018 and held it in 1 quarter. The position peaked at $12K in Q4 2018. 656 funds tracked by Wall St. Rank hold DGX as of Q1 2019.

Claybrook Capital reported no remaining Quest Diagnostics position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 150 Quest Diagnostics shares in Q1 2019, an estimated $12K.
Claybrook Capital first reported a position in Quest Diagnostics in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Quest Diagnostics position peaked at $12K in Q4 2018.
656 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.